Citius Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com December 6

Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com

CRANFORD, N.J., Nov. 29, 2018 /PRNewswire/ -- Citius Pharmaceuticals (NASDAQ: CTXR), based in New Jersey, focused on specialty pharmaceuticals in adjunctive cancer care and critical care, today announced that Myron Holubiak, CEO, will present live at VirtualInvestorConferences.com on December 6, 2018.

DATE: Thursday, December 6, 2018
TIME: 9:15 am ET
LINK:https://tinyurl.com/126prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at www.VirtualInvestorConferences.com.

Recent Company Highlights

• The Citius Scientific Advisory Board (SAB) meeting was held on October 4, 2018 to discuss the progress of the Mino-Lok® pivotal phase 3 trial. Twenty investigational sites have been initiated with another 15 in "start up" mode awaiting final IRB approvals or contract signatures.
• On October 2, 2018, Citius received notice from MD Anderson Cancer Center ("MDACC") that the US Patent and Trademark Office ("USPTO") issued United States Patent Number 10/086,114 entitled "Antimicrobial Solutions with Enhanced Stability". Citius also received official notification from MDACC that the European Patent Application (No. 16806326.1) for Mino-Lok with Enhanced Stability was published (September 12, 2018) under serial number 3370794.
• Citius has selected a higher potency corticosteroid in its steroid/anesthetic topical formulation program for the treatment of hemorrhoids. The new formulation, CITI-002, will combine lidocaine with a higher potency corticosteroid. The Company held a Type C meeting with FDA to discuss the results of the Phase 2a study and obtained the Agency's view on development plans to support the potential formulation change. The pre-clinical and clinical development programs for CITI-002 will be similar to those conducted in CITI-001 development.

About Citius Pharmaceuticals

Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius product candidates aim to offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development. Citius is currently advancing two proprietary product candidates, our Mino-Lok^® product and CITI-002, a corticosteroid/lidocaine formulation. Citius believes the markets for its product candidates are large and underserved by the current standard of care.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

View original content to download multimedia:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-webcast-live-at-virtualinvestorconferencescom-december-6-300757844.html

SOURCE Citius Pharmaceuticals